Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis

Hwang,Ki-Eun; Park,Do-Sim; Kim,Young-Suk; Kim,Byoung-Ryun; Park,Seong-Nam; Lee,Mi-Kyung; Park,Seong-Hoon; Yoon,Kwon-Ha; Jeong,Eun-Taik; Kim,Hak-Ryul

doi:10.3892/ijo.2013.1918

Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis

Authors:
- Ki-Eun Hwang
- Do-Sim Park
- Young-Suk Kim
- Byoung-Ryun Kim
- Seong-Nam Park
- Mi-Kyung Lee
- Seong-Hoon Park
- Kwon-Ha Yoon
- Eun-Taik Jeong
- Hak-Ryul Kim
View Affiliations

Affiliations: Department of Internal Medicine, Institute of Wonkwang Medical Science, Wonkwang University, School of Medicine, Iksan, Jeonbuk 570-749, Republic of Korea, Department of Laboratory Medicine, Institute of Wonkwang Medical Science, Wonkwang University, School of Medicine, Iksan, Jeonbuk 570-749, Republic of Korea, Department of Obstetrics and Gynecology, Wonkwang University, School of Medicine, Iksan, Jeonbuk 570-749, Republic of Korea, Department of Thoracic and Cardiovascular Surgery, Wonkwang University, School of Medicine, Iksan, Jeonbuk 570-749, Republic of Korea, Department of Radiology, Wonkwang University, School of Medicine, Iksan, Jeonbuk 570-749, Republic of Korea
Published online on: April 24, 2013 https://doi.org/10.3892/ijo.2013.1918
Pages: 72-78

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression levels of Prx1 are frequently elevated in several human cancers, including lung cancer and may confer increased resistance to treatment. In this study, we investigated the role of Prx1 in docetaxel-induced apoptosis in A549 lung cancer cells. To test whether Prx1 knockdown affected the sensitivity of A549 cells to docetaxel treatment, we generated short hairpin RNA (shRNA) constructs targeting Prx1 and analyzed the effect of Prx1 knockdown on growth and apoptosis. Tumor growth was evaluated in scrambled shRNA- or shPrx1-infected A549 cell tumors receiving docetaxel treatment. In addition, mechanistic information was gathered by western blot analysis from cell lysates of scrambled- and shPrx1-infected A549 cells pretreated with or without LY294002 and subsequently treated with docetaxel. We found that Prx1 knockdown resulted in enhanced docetaxel-induced cytotoxicity in a dose-dependent manner. In vivo, the growth rate of shPrx1-infected A549 tumors was significantly reduced compared to that of scrambled shRNA-infected A549 tumors. Prx1 knockdown also augmented the inhibitory effects of docetaxel on tumor growth. Prx1 knockdown increased the apoptotic potential through activation of the caspase cascade and suppressed docetaxel-induced phosphorylation of Akt and its substrate forkhead box O1 (FOXO1). Moreover, treatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 reduced the phosphorylation of FOXO1 and increased the cytotoxicity of docetaxel in A549 cells. Our findings suggest that Prx1 may modulate the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 60:277–300. 2010.
2.	Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Ree SG, Kang SW, Chang TS, Jeong W and Kim K: Peroxiredoxin, a novel family of peroxidases. IUBMB Life. 52:35–41. 2001. View Article : Google Scholar
4.	Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, Omura K, Suzuki H and Yoshida H: Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 145:127–132. 1999. View Article : Google Scholar : PubMed/NCBI
5.	Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, Omura K, Harada H, Suzuki H and Yoshida H: Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 156:27–35. 2000. View Article : Google Scholar : PubMed/NCBI
6.	Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 21:2085–2090. 2001.PubMed/NCBI
7.	Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M and Kinnula VL: Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 111:514–521. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, Park EM and Park YM: Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol. 19:285–298. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Chang JW, Lee SH, Jeong JY, Chae HZ, Kim YC, Park ZY and Yoo YJ: Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett. 579:2873–2877. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Chen MF, Keng PC, Shau H, Wu CT, Hu YC, Liao SK and Chen WC: Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys. 64:581–591. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Kim YJ, Lee WS, IP C, Chae HZ, Park EM and Park YM: Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res. 66:7136–7142. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Gligorov J and Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 9(Suppl 2): S3–S8. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Posner MR: Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs. 12(Suppl 1): S21–S24. 2001.
14.	Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 48:353–374. 1997. View Article : Google Scholar : PubMed/NCBI
15.	Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103. 2000.
16.	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Bhalla KN: Microtubule-targeted anticancer agents and apoptosis. Oncogene. 56:9075–9085. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1253–1255. 1996.PubMed/NCBI
19.	Haldar S, Basu A and Croce CM: Bcl2 is the guardian of micro-tubule integrity. Cancer Res. 57:229–233. 1997.PubMed/NCBI
20.	Lee LF, Li G, Templeton DJ and Ting JP: Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c–Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem. 273:28253–28260. 1998.
21.	Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR and Chiles TC: Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res. 58:241–247. 1998.
22.	Mhaidat NM, Wang Y, Kiejda KA, Zhang XD and Hersey P: Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther. 6:752–761. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Mhaidat NM, Zhang XD, Jiang CC and Hersey P: Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 13:1308–1314. 2007. View Article : Google Scholar
24.	MacKeigan JP, Taxman DJ, Hunter D, Earp HS III, Graves LM and Ting JP: Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res. 8:2091–2099. 2002.
25.	Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3’-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62:1087–1092. 2002.
26.	Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 23:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Chhipa RR, Lee KS, Onate S, Wu Y and Ip C: Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res. 7:1543–1552. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Crissman HA and Steinkamp JA: Cell cycle-related changes in chromatin structure detected by flow cytometry using multiple DNA fluorochromes. Eur J Histochem. 37:129–138. 1993.PubMed/NCBI
29.	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
30.	Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol. 17:1061–1070. 1999.PubMed/NCBI
31.	Montegomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R and Stahl WL: Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate. 65:141–150. 2005. View Article : Google Scholar : PubMed/NCBI
32.	Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ and Hung MC: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21^Cip1, which inhibits p34Cdc2 kinase. Mol Cell. 2:581–591. 1998. View Article : Google Scholar : PubMed/NCBI
33.	Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL and Plymate SR: Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody and docetaxel against prostate cancer tumors. Clin Cancer Res. 12:6153–6160. 2006. View Article : Google Scholar : PubMed/NCBI
34.	Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y and Ma D: Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 261:108–119. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E and Oya M: Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol. 185:2376–2381. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW and Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK and Arden KC: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor of FKHR1. Proc Natl Acad Sci USA. 96:7421–7426. 1999. View Article : Google Scholar : PubMed/NCBI
38.	Kops GJ and Burgering BM: Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med. 77:656–665. 1999. View Article : Google Scholar : PubMed/NCBI
39.	Nakae J, Park BC and Accili D: Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem. 274:15982–15985. 1999. View Article : Google Scholar
40.	Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forehead transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
41.	Suhara T, Kim HS, Kirshenbaum LA and Walsh K: Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol. 22:680–691. 2002. View Article : Google Scholar : PubMed/NCBI
42.	Dijkers PF, Medema RH, Lammers JW, Koenderman L and Coffer PJ: Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 10:1201–1204. 2000. View Article : Google Scholar : PubMed/NCBI
43.	Modur V, Nagarajan R, Evers BM and Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem. 277:47928–47937. 2002. View Article : Google Scholar : PubMed/NCBI
44.	Kavurma MM and Khachigian LM: Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ. 10:36–44. 2003. View Article : Google Scholar : PubMed/NCBI
45.	Lee YJ, Park MY and Kang YA: Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib of IGF-1R blockade. Tuberc Respir Dis. 63:42–51. 2007. View Article : Google Scholar
46.	Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
47.	Sunters A, Femandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC and Lam EW: FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 278:49795–49805. 2003. View Article : Google Scholar : PubMed/NCBI